Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy

Immunotherapy using checkpoint blockade (ICB) with antibodies such as anti-PD-1 has revolutionised the treatment of many cancers. Despite its use to treat COVID-19 patients and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, the effect of hydroxychloroquine (HCQ) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Krueger, Janna, Santinon, Francois, Kazanova, Alexandra, Issa, Mark E., Larrivee, Bruno, Kremer, Richard, Milhalcioiu, Catalin, Rudd, Christopher E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238207/
https://www.ncbi.nlm.nih.gov/pubmed/34181666
http://dx.doi.org/10.1371/journal.pone.0251731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238207/
https://www.ncbi.nlm.nih.gov/pubmed/34181666
http://dx.doi.org/10.1371/journal.pone.0251731

Ejemplares similares